Who Paid My Doc
Heena Shah Patel
Allergy & Immunology Upland, CA Medical Doctor
NPI 1881916864 CMS profile 1312872
1282 W Arrow Hwy Ste 100, Ste B101, Upland, CA 91786
General payments
$427,983
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$265,951
Through program year 2025, Heena Shah Patel of Upland, CA is reported in the CMS Open Payments database as having received $427,983 across 1,233 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $265,951 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $70,030 | 232 | |
| 2024 | General | $98,870 | 215 | |
| 2023 | General | $140,239 | 305 | |
| 2022 | General | $30,066 | 154 | |
| 2021 | General | $32,840 | 151 | |
| 2020 | General | $16,258 | 57 | |
| 2019 | General | $39,680 | 119 |
Beside peers
- Heena Shah Patel
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Heena Shah Patel were reported at $70,030. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.
Show as a table
| Year | Heena Shah Patel | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $39,680 | $594 | $163–$1,512 | $163 |
| 2020 | $16,258 | $426 | $106–$1,233 | $114 |
| 2021 | $32,840 | $638 | $157–$1,708 | $132 |
| 2022 | $30,066 | $790 | $205–$1,961 | $149 |
| 2023 | $140,239 | $852 | $220–$2,147 | $160 |
| 2024 | $98,870 | $865 | $203–$2,267 | $164 |
| 2025 | $70,030 | $1,140 | $272–$2,892 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
352
Drug cost
$597,178
Branded share of claims
48.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Panzyga Immun Glob G(Igg)-Ifas/Glycine | Brand | 26 | $249,802 | |
| Dupixent Syringe Dupilumab | Brand | 37 | $138,229 | |
| Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 11 | $89,828 | |
| Dupixent Pen Dupilumab | Brand | 16 | $67,932 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 29 | $21,827 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 16 | $16,322 | |
| Cromolyn Sodium | Generic | 15 | $4,484 | |
| Epinephrine | Generic | 12 | $2,616 | |
| Tacrolimus | Generic | 11 | $2,180 | |
| Azelastine Hcl | Generic | 39 | $1,323 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 27 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| NUCALA |
|
$85,019 | — | — |
| OPZELURA |
|
$8,128 | — | — |
| DUPIXENT |
|
$3,617 | 53 | — |
| RINVOQ |
|
$248 | — | — |
| TEZSPIRE |
|
$228 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 27 with PatronRecords
1,233 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in California
Raffi Tachdjian
Allergy & Immunology · Santa Monica, CA
Bob Geng
Allergy & Immunology · San Diego, CA
Vinay Mehta
Allergy & Immunology · Laguna Niguel, CA
Andrew White
Allergy & Immunology · San Diego, CA
Marc Riedl
Allergy & Immunology · San Diego, CA
Katharine Woessner
Allergy & Immunology · San Diego, CA
Related records
Allergy & Immunology in California
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.